Stock performance

Boston Scientific (BSX) stock rose from $24.79 at the close of market on December 29, 2017, to $34.80 at the close of market on November 23, 2018, reflecting a rise of ~40% year-to-date. On November 23, Boston Scientific stock closed at $34.80, a ~42% rise from its 52-week low of $24.54 on December 6, 2017.

Boston Scientific hit its 52-week high of $39.44 on October 2.

Why Analysts Are Mostly Positive on Boston Scientific Stock

Financials in a nutshell

Boston Scientific’s net sales in the first nine months of this year totaled $7.3 billion compared to $6.6 billion in the same period of the previous year, reflecting ~9% YoY growth. In the third quarter, Boston Scientific’s medical equipment peers Zimmer Biomet Holdings (ZBH), Edwards Lifesciences (EW), and Stryker (SYK) reported revenues of $1.8 billion, $906.6 million, and $3.2 billion, respectively, reflecting rises of ~1.02%, ~8.12%, and 7.85%, respectively, YoY.

The revenue growth of Boston Scientific, Zimmer Biomet Holdings, Edwards Lifesciences, and Stryker could boost the share price of the iShares U.S. Medical Devices ETF (IHI). BSX, ZBH, EW, and SYK make up ~4.93%, ~2.86%, ~3.70%, and 5.16% of IHI’s total portfolio holdings, respectively.

The company reported a gross profit of $5.2 billion in the first nine months of 2018 compared to $4.7 billion in the same period of 2017.

Boston Scientific’s net income and diluted EPS in the first nine months of 2018 amounted to $1.3 billion and $0.92, respectively, compared to $719.0 million and $0.52, respectively, in the same period of the previous year.

After its third-quarter financial results, Boston Scientific updated its full-year financial guidance. The company expects its net revenue in 2018 to be in the range of $9.79 billion–$9.83 billion.

Analysts’ recommendations

Of the 22 analysts tracking Boston Scientific stock in November, 15 have given it “strong buys,” while five have given it “buys.” Two analysts have given it “holds.”

On November 26, Boston Scientific had a consensus 12-month target price of $42.29, which represents a potential ~21.52% return on investment over the next 12 months.

Latest articles

16 Jul

Q2 Earnings Were a Mixed Bag for J.B. Hunt

WRITTEN BY Anirudha Bhagat

J.B. Hunt reported mixed Q2 earnings, as its revenues grew YoY but earnings declined.

16 Jul

What to Expect From Nucor’s Q2 Earnings This Week

WRITTEN BY Mohit Oberoi, CFA

Nucor is scheduled to release its second-quarter earnings on Thursday. The company has seen an upwards price action of 7.4% year-to-date.

16 Jul

Will HollyFrontier's Q2 Results Improve?

WRITTEN BY Maitali Ramkumar

HollyFrontier (HFC) is expected to release its second-quarter results on August 1.

On Monday, Citigroup downgraded Tiffany (TIF) stock to “neutral” from “buy” and reduced its target price to $100 from $115 per share.

16 Jul

AT&T’s WarnerMedia Segment to Cut Jobs

WRITTEN BY Ambrish Shah

AT&T’s WarnerMedia segment is planning job cuts from its ad sales unit as the company continues to reorganize the businesses it acquired.